← SynDRA
CRIZOTINIB
SynDRA canonical compound SYN0020688 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | MET |
|---|
| Mechanism of action | ALK inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- ALK
- MET
- ROS1
- MST1R
- AAK1
- PRKAA1
- NTRK1
- NTRK2
- NTRK3
- NUAK2
- PIP5K1A
- PLK4
Mechanisms of action (all sources)
- ALK INHIBITOR
- MET INHIBITOR
- Hepatocyte growth factor receptor inhibitor
- ALK tyrosine kinase receptor inhibitor
- ROS1 INHIBITOR
- Proto-oncogene tyrosine-protein kinase ROS inhibitor
- MST1R INHIBITOR
- Macrophage-stimulating protein receptor inhibitor
- MET MODULATOR
- ROS1 MODULATOR
- ALK MODULATOR
Drug classes
- Receptor Tyrosine Kinase Inhibitors
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 2B6 Inhibitors
- P-Glycoprotein Inhibitors
- Organic Cation Transporter 2 Inhibitors
- Cytochrome P450 3A Inhibitors
- Organic Cation Transporter 1 Inhibitors
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- xalkori
- PF-02341066
- Pf-2341066
- NSC-756645
- Xalkori
- Xalkori (TN)
- novel ALK inhibitors
- PF 02341066
- (R)-crizotinib
- PF 2341066
- Crizotinib (PF-02341066)
- (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
- 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1H-pyrazol-4-yl]-2-pyridinamine
- Crizotinib (PF-2341066)
- PF2341066
- CHEMBL601719
- CHEBI:64310
- 877399-52-5 (free base)
- 53AH36668S
- NSC 756645
- 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl]pyridin-2-amine
- 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-
- 3-[(1r)-1-(2,6-Dichloro-3-Fluorophenyl)ethoxy]-5-(1-Piperidin-4-Yl-1h-Pyrazol-4-Yl)pyridin-2-Amine
- 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
- (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine
- Crizotinib [USAN]
- Crizotinib [USAN:INN]
- crizotinibum
- UNII-53AH36668S
- 3-[(1R)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine
- VGH
- Crizotinib- Bio-X
- CRIZOTINIB [MI]
- CRIZOTINIB [INN]
- CRIZOTINIB [JAN]
- PF02341066
- CRIZOTINIB [VANDF]
- CRIZOTINIB [MART.]
Reported adverse events
- Abdominal discomfort
- Abdominal pain
- Abdominal tenderness
- Blood creatinine increased
- Bradycardia
- Chills
- Constipation
- Cough
- Diplopia
- Dizziness
- Dysgeusia
- Dyspepsia
Look up CRIZOTINIB in the interactive SynDRA portal →